<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-139435</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Behçet&#146; disease</dc:title>
<dc:description xml:lang="en">Case report: A 24 year old woman who complained of maculo-papulo rash, genital and bucal aphthous ulcers, abdominal pain, minor dyspnea and visual loss in both eyes. Funduscopy revealed a bilateral occlusive vasculitis including central vessels. Treatment was initiated with a methylprednisolone bolus (1 g/24 h) and infliximab 5 mg/kg/day (0-2-6 weeks and every 8 weeks). The treatment prescribed induced a fast remission. Visual acuity improved. The patient did not suffer any other relapse after one year of follow-up. Discussion: An initial treatment with Infliximab should be considered in Behçet disease for serious outbreaks, such as macular occlusive vasculitis with ischemia (AU)</dc:description>
<dc:creator>Peraza-Nieves, J. E</dc:creator>
<dc:creator>Bañeros-Rojas, P</dc:creator>
<dc:creator>Díaz-Valle, D</dc:creator>
<dc:creator>Berrozpe-Villabona, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Mujer de 24 años con rash maculopapular, aftas orales y genitales, dolor abdominal, disnea  leve y disminución de la agudeza visual en ambos ojos. La funduscopia reveló una vasculitis oclusiva bilateral que incluía los vasos centrales. Se inició tratamiento con bolos de metilprednisolona (1 g/24 h) e infliximab 5 mg/kg/día (0-2-6 semanas y cada 8 semanas). El tratamiento indujo una rápida remisión. La agudeza visual mejoró. Tras un año de seguimiento no ha presentado ningún nuevo brote. Discusión: Un tratamiento de inicio con infliximab debe considerarse en brotes graves de enfermedad de Behçet como una vasculitis oclusiva bilateral con isquemia (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;90(6): 285-288, jun. 2015. ilus</dc:source>
<dc:identifier>ibc-139435</dc:identifier>
<dc:title xml:lang="es">Terapia de inicio con infliximab en una vasculitis oclusiva bilateral como inicio de una enfermedad de Behçet</dc:title>
<dc:subject>^d4479^s22012</dc:subject>
<dc:subject>^d4479^s22024</dc:subject>
<dc:subject>^d4479^s22032</dc:subject>
<dc:subject>^d24366^s22033</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d4479^s22016</dc:subject>
<dc:subject>^d13669^s22024</dc:subject>
<dc:subject>^d13669^s22044</dc:subject>
<dc:subject>^d13669^s22012</dc:subject>
<dc:subject>^d13669^s22053</dc:subject>
<dc:subject>^d15059^s22012</dc:subject>
<dc:subject>^d15059^s22013</dc:subject>
<dc:subject>^d15059^s22032</dc:subject>
<dc:subject>^d24366^s22031</dc:subject>
<dc:subject>^d15059^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
